On the prodrug potential of novel aldose reductase inhibitors with diphenylmethyleneaminooxycarboxylic acid structure

European Journal of Pharmaceutical Sciences

Volumn 15, Issue 1, 2002, Pages 11-20

  Rakowitz, Dietmar ^a   Matuszczak, Barbara ^a   Gritsch, Stefan ^a   Hofbauer, Peter ^a   Krassnigg, Andreas ^a   Costantino, Luca ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Aldose reductase inhibitors; Diphenylmethyleneaminooxycarboxylic acids; Enzymatic hydrolysis; Oxime ethers; Prodrugs

Indexed keywords

ENZYME INHIBITION; ESTERS; HYDROLYSIS; PH EFFECTS;

INCUBATION;

CARBOXYLIC ACIDS;

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; CARBOXYLIC ACID DERIVATIVE; CHOLINESTERASE; DIPHENYLMETHYLENEAMINOOXYCARBOXYLIC ACID; ESTER DERIVATIVE; ESTERASE; PRODRUG; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DEGRADATION; DRUG HYDROLYSIS; ENZYMATIC DEGRADATION; IC 50; INCUBATION TIME; PH; PRIORITY JOURNAL;

ALDEHYDE REDUCTASE; ANIMALS; BENZHYDRYL COMPOUNDS; CARBOXYLIC ACIDS; CATTLE; ENZYME INHIBITORS; HYDROLYSIS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036173524     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(01)00192-0     Document Type: Article

References (26)

1. Tolrestat
2. Epalrestat
3. ICI-128436
4. FR-74366
5. Zopolrestat
6. Benzothiazole aldose reductase inhibitors
7. Pyridazino[3,4-b][1,5]benzoxazepin-5(6H)-ones: Synthesis and biological evaluation
8. Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof, and process for their manufacture
9. Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities
10. New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications
11. Synthesis, activity and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors
12. Synthesis of ω-aminooxy acids by oxygen-alkyl fission of lactones
13. Novel aldose reductase inhibitors: Synthesis and structure-activity studies of (3-benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl)acetic acids
14. The role of aldose reductase in the development of diabetic complications
15. Aldose reductase inhibitors: A potential new class of agents for the pharmacological control of certain diabetic complications
16. Aldose reductase inhibitors as a new approach to the treatment of diabetic complications
17. Cholinesterase im Serum
18. Novel, potent aldose reductase inhibitors: 3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1- phthalazineacetic acid (zopolrestat) and congeners
19. New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them
20. Diabetes complications: Why is glucose potentially toxic?
21. A series of diarylsubstituted oximes as potential substrate for new aldose reductase inhibitors
22. Aldose reductase inhibitors: Recent developments
23. N-[[5-(Trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-N- methylglycine (tolrestat), a potent, orally active aldose reductase inhibitor
24. Effects of a new aldose reductase inhibitor on various tissues in vitro